Showing 4081-4090 of 5646 results for "".
- Verana Health to Present Findings of Studies Using AAO IRIS Registry Data to Advance Insights into Real World Outcomes in Treating AMDhttps://modernod.com/news/verana-health-to-present-findings-of-studies-using-aao-iris-registry-data-to-advance-insights-into-real-world-outcomes-in-treating-amd/2481222/During The Retina Society’s 55th Annual Scientific Meeting Nov. 2-5, Verana Health will present findings on two studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy)
- Aramis Biosciences Completes Enrollment of its Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/Aramis Biosciences announced the completion of enrollment in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “We are very pleased to have completed the enrollment of our phas
- Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/2481217/Neurotech Pharmaceuticals announced positive topline results in two replicative phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that res
- Replay Launches Its First HSV Gene Therapy Company, Eudora, Focused on Retinal Eye Diseasehttps://modernod.com/news/replay-launches-its-first-hsv-gene-therapy-company-eudora-focused-on-retinal-eye-disease/2481216/Replay announced the launch of Eudora, an HSV gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV. Eudora’s co-founders, Professors Joe Glor
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republichttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-the-czech-republic/2481212/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribu
- Heru Makes Appointments to Its Executive Leadership Teamhttps://modernod.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/Heru announced several key executive appointments across its leadership team and board of directors designed to strengthen the company’s commercial operation and support its next phase of growth. Fred Drasner has been appointed as Heru’s Chairman of the Board of
- Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470https://modernod.com/news/nicox-reports-achieving-primary-objective-in-mont-blanc-the-first-phase-3-glaucoma-trial-for-ncx-470/2481209/Nicox SA announced that once daily dosing of NCX 470 0.1% met the primary objective of noninferiority in lowering IOP compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.</
- Outlook Therapeutics Announces Acceptance of BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2481206/Outlook Therapeutics announced that the FDA has accepted for filing a Biologics License Application (BLA) for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD). The FDA set
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- EyeMed Vision Care Names Matt MacDonald Presidenthttps://modernod.com/news/eyemed-vision-care-names-matt-macdonald-president/2481204/EyeMed has appointed Matt MacDonald to the role of President. Mr. MacDonald succeeds Lukas Ruecker who has decided to step down after 9 years for personal reasons. Mr. MacDonald has been with EyeMed since 2013, and most recently served as Chief Operations Officer. Prior to that, he